BMND3
MCID: BNM018
MIFTS: 33

Bone Mineral Density Quantitative Trait Locus 3 (BMND3)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Bone Mineral Density Quantitative Trait Locus 3

MalaCards integrated aliases for Bone Mineral Density Quantitative Trait Locus 3:

Name: Bone Mineral Density Quantitative Trait Locus 3 57
Bone Mineral Density, Low, Susceptibility to 57 6
Bone Mineral Density, Low 57
Low Bone Mineral Density 6
Bmnd3 57

Classifications:



External Ids:

OMIM® 57 606928

Summaries for Bone Mineral Density Quantitative Trait Locus 3

MalaCards based summary : Bone Mineral Density Quantitative Trait Locus 3, also known as bone mineral density, low, susceptibility to, is related to bone mineral density quantitative trait locus 17 and calvarial doughnut lesions with bone fragility. An important gene associated with Bone Mineral Density Quantitative Trait Locus 3 is BMND3 (Bone Mineral Density Variability 3). The drugs Risedronate and Zoledronic Acid have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and heart.

More information from OMIM: 606928

Related Diseases for Bone Mineral Density Quantitative Trait Locus 3

Diseases in the Bone Mineral Density Quantitative Trait Locus 15 family:

Bone Mineral Density Quantitative Trait Locus 4 Bone Mineral Density Quantitative Trait Locus 18
Bone Mineral Density Quantitative Trait Locus 1 Bone Mineral Density Quantitative Trait Locus 2
Bone Mineral Density Quantitative Trait Locus 3 Bone Mineral Density Quantitative Trait Locus 5
Bone Mineral Density Quantitative Trait Locus 6 Bone Mineral Density Quantitative Trait Locus 7
Bone Mineral Density Quantitative Trait Locus 8 Bone Mineral Density Quantitative Trait Locus 9
Bone Mineral Density Quantitative Trait Locus 10 Bone Mineral Density Quantitative Trait Locus 11
Bone Mineral Density Quantitative Trait Locus 12 Bone Mineral Density Quantitative Trait Locus 13
Bone Mineral Density Quantitative Trait Locus 14 Bone Mineral Density Quantitative Trait Locus 16
Bone Mineral Density Quantitative Trait Locus 17

Diseases related to Bone Mineral Density Quantitative Trait Locus 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 227)
# Related Disease Score Top Affiliating Genes
1 bone mineral density quantitative trait locus 17 11.6
2 calvarial doughnut lesions with bone fragility 11.5
3 celiac disease 1 11.3
4 hypophosphatasia, childhood 11.2
5 mucolipidosis iii alpha/beta 11.2
6 mucolipidosis iii gamma 11.2
7 multicentric osteolysis, nodulosis, and arthropathy 11.2
8 rothmund-thomson syndrome, type 2 11.2
9 winchester syndrome 11.2
10 dyskeratosis congenita 11.2
11 idiopathic infantile hypercalcemia 11.2
12 bone mineral density quantitative trait locus 8 11.1
13 bone mineral density quantitative trait locus 15 11.1
14 osteoporosis 11.1
15 bone resorption disease 10.8
16 inflammatory bowel disease 10.7
17 rickets 10.7
18 spondyloarthropathy 1 10.6
19 bone disease 10.6
20 inflammatory spondylopathy 10.6
21 spondylitis 10.6
22 crohn's disease 10.6
23 systemic lupus erythematosus 10.6
24 lupus erythematosus 10.6
25 hyperparathyroidism 10.6
26 rheumatoid arthritis 10.5
27 cystic fibrosis 10.5
28 body mass index quantitative trait locus 1 10.5
29 amenorrhea 10.5
30 liver disease 10.5
31 arthritis 10.5
32 ulcerative colitis 10.5
33 osteonecrosis 10.5
34 atherosclerosis susceptibility 10.4
35 scoliosis 10.4
36 osteomalacia 10.4
37 hypogonadism 10.4
38 fatty liver disease 10.4
39 secondary hyperparathyroidism 10.4
40 hypothyroidism 10.4
41 chronic kidney disease 10.4
42 hyperthyroidism 10.4
43 thalassemia 10.4
44 fibrosis of extraocular muscles, congenital, 1 10.4
45 anorexia nervosa 10.4
46 colitis 10.4
47 non-alcoholic fatty liver disease 10.4
48 eating disorder 10.4
49 multiple sclerosis 10.3
50 scoliosis, isolated 1 10.3

Graphical network of the top 20 diseases related to Bone Mineral Density Quantitative Trait Locus 3:



Diseases related to Bone Mineral Density Quantitative Trait Locus 3

Symptoms & Phenotypes for Bone Mineral Density Quantitative Trait Locus 3

Clinical features from OMIM®:

606928 (Updated 20-May-2021)

Drugs & Therapeutics for Bone Mineral Density Quantitative Trait Locus 3

Drugs for Bone Mineral Density Quantitative Trait Locus 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
2
Zoledronic Acid Approved Phase 4 118072-93-8 68740
3
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
4
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
5
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
6 calcium channel blockers Phase 4
7 Vitamins Phase 4
8 Calciferol Phase 4
9 Diphosphonates Phase 4
10 Anti-Retroviral Agents Phase 4
11 Raltegravir Potassium Phase 4
12 Antiviral Agents Phase 4
13 Anti-HIV Agents Phase 4
14 Anti-Infective Agents Phase 4
15 HIV Integrase Inhibitors Phase 4
16 Integrase Inhibitors Phase 4
17 Estrogen Antagonists Phase 4
18 Raloxifene Hydrochloride Phase 4
19 Estrogen Receptor Antagonists Phase 4
20 Estrogen Receptor Modulators Phase 4
21 Calcium, Dietary Phase 4
22 Ibandronic Acid Phase 4
23
Calcium Nutraceutical Phase 4 7440-70-2 271
24
Alendronate Approved Phase 3 121268-17-5, 66376-36-1 2088
25
Denosumab Approved Phase 3 615258-40-7
26
Ritonavir Approved, Investigational Phase 3 155213-67-5 392622
27
Dolutegravir Approved Phase 3 1051375-16-6 54726191
28
Lamivudine Approved, Investigational Phase 3 134678-17-4 60825
29 Cytochrome P-450 CYP3A Inhibitors Phase 3
30 HIV Protease Inhibitors Phase 3
31 Cytochrome P-450 Enzyme Inhibitors Phase 3
32
protease inhibitors Phase 3
33
Etidronic acid Approved Phase 2 2809-21-4, 7414-83-7 3305
34
Calcium carbonate Approved, Investigational Phase 2 471-34-1
35 Immunoglobulins Phase 2
36 Antibodies Phase 2
37 Antibodies, Monoclonal Phase 2
38 Micronutrients Phase 2
39 Trace Elements Phase 2
40 Nutrients Phase 2
41 Antacids Phase 2
42 Anti-Ulcer Agents Phase 2
43
Parathyroid hormone Approved, Investigational Phase 1 9002-64-6
44
Abaloparatide Approved, Investigational Phase 1 247062-33-5
45
Etanercept Approved, Investigational Phase 1 185243-69-0
46 Immunologic Factors Phase 1
47 Gastrointestinal Agents Phase 1
48 Antirheumatic Agents Phase 1
49 Immunosuppressive Agents Phase 1
50 Anti-Inflammatory Agents, Non-Steroidal Phase 1

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients Completed NCT01215890 Phase 4 risedronate;placebo
2 Switch From Tenofovir to Raltegravir for Low Bone Mineral Density Completed NCT00939874 Phase 4 Raltegravir
3 A Multi-center, Randomized, Double-blind, Double-dummy Study in Postmenopausal Women With Low Bone Mineral Density to Compare the Effects of a Single Dose of i.v. Zoledronic Acid 5 mg, With Daily Oral Raloxifene 60 mg OD on Bone Turnover Markers Completed NCT00431444 Phase 4 Raloxifene;Zoledronic acid;Placebo oral pills;Placebo intravenous (i.v.) infusion
4 Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density Not yet recruiting NCT04597931 Phase 4 Romosozumab;Zoledronic Acid
5 The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density Terminated NCT00446589 Phase 4 ibandronate;teriparatide
6 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
7 A Multicenter, Randomized, Cross-Over, Open-label Study to Evaluate the Adherence, Preference, and Satisfaction of Denosumab and Alendronate in Postmenopausal Women With Low Bone Mineral Density Completed NCT00518531 Phase 3 alendronate;denosumab
8 A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density Completed NCT00515463 Phase 3
9 An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density Completed NCT00325468 Phase 3 AMG 162
10 A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Compare the Efficacy and Safety of Denosumab Versus Placebo in Males With Low Bone Mineral Density Completed NCT00980174 Phase 3 60 mg denosumab
11 A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women With Low Bone Mineral Density Completed NCT00377819 Phase 3 alendronate;Denosumab (AMG 162)
12 MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM PROTEASE INHIBITORS TO DOLUTEGRAVIR IN HIV-1-INFECTED SUBJECTS WITH LOW BONE MINERAL DENSITY Completed NCT01966822 Phase 3 Dolutegravir, 50mg every 24 hours;Protease Inhibitor/ritonavir
13 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a 91-Day Extended-Cycle Combination Oral Contraceptive (Seasonale) for the Treatment of Low Bone Mineral Density in Adolescent Females With Secondary Amenorrhea and Osteopenia Withdrawn NCT00117260 Phase 3 Seasonale (levonorgestrel and ethinyl estradiol)
14 A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density Completed NCT01406548 Phase 2 BPS804;Placebo;BPS804;Placebo;BPS804;Placebo
15 A Randomised, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density Completed NCT00896532 Phase 2 Placebo to Romosozumab;Alendronate;Teriparatide;Romosozumab;Denosumab;Placebo to Denosumab;Zoledronic acid
16 A Randomized, Double-Blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Postmenopausal Women With Low Bone Mineral Density Completed NCT00043186 Phase 2 Placebo;Denosumab;Alendronate
17 Active-controlled, Double-blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly in Postmenopausal Women With Low Bone Mineral Density Completed NCT00577837 Phase 2 risedronate;risedronate;risedronate;experimental
18 Impact of Oral Alendronate Therapy on Bone Mineral Density in HIV-infected Children and Adolescents With Low Bone Mineral Density Completed NCT00921557 Phase 2 Alendronate;Placebo
19 A Phase 2 Randomized Study of LY2541546 Versus Placebo in Postmenopausal Women With Low Bone Mineral Density: An Evaluation of the Dose Response Relationship Using Bone Mineral Density Completed NCT01144377 Phase 2 LY2541546;Placebo
20 A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density Completed NCT00293813 Phase 2 Alendronate;Denosumab;Placebo
21 A Phase 2, 24-Week, Multicenter, Randomized, Parallel-Group, Dose-Ranging Study To Evaluate The Effect Of Teriparatide Nasal Spray On Bone Mineral Density In Postmenopausal Women With Low Bone Mineral Density Withdrawn NCT00624481 Phase 2 Teriparatide;Teriparatide Nasal Spray;Teriparatide Nasal Spray;Teriparatide Nasal Spray;Teriparatide Nasal Spray
22 Changes in Bone Mineral Density as Measured by Calcaneal Quantitative Ultrasound in Third Trimester of Pregnancy Completed NCT02480023 Phase 1
23 An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate Completed NCT01588509 Phase 1 Romosozumab
24 A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Effect of AMG 785 on Parameters of Bone Quality of the Forearm Using pQCT in Postmenopausal Women With Low Bone Mineral Density Completed NCT00950950 Phase 1 Romosozumab;Placebo
25 A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density Completed NCT01101048 Phase 1 Placebo;AMG 167
26 A Prospective, Single Arm Study to Evaluate the PK, PD and Usability of Abaloparatide-sMTS in Postmenopausal Women With Low Bone Mineral Density Completed NCT04366726 Phase 1
27 The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Bone Mineral Density and Rheumatoid Arthritis Terminated NCT01294397 Phase 1 Etanercept;Denosumab
28 Effects of Whole Body Vibration and Pilates Method on Bone Mineral Density in Postmenopausal Women: a Randomized, Controlled, Clinical Trial Completed NCT02769143
29 Radiological, Biological, Genetic and Micro-architectural Bone Determinants of Fractures in Men With Low Bone Mineral Density Completed NCT01250314
30 HIV UPBEAT: Understanding the Pathology of Bone Disease in HIV-infected. A Prospective Cohort Study of HIV-infected Patients and HIV-negative Subjects. Recruiting NCT01778361
31 Impact of Scaling and Root Planing on Systemic Inflammation and Serum Bone Resorption Markers in Premenopausal Women With Periodontitis and Low Bone Mineral Density- A Prospective Interventional Study. Recruiting NCT04259242
32 Impact of Scaling and Root Planing on Systemic Inflammation and Serum Bone Resorption Markers in Postmenopausal Women With Low Bone Mineral Density With Periodontitis. Recruiting NCT04261491

Search NIH Clinical Center for Bone Mineral Density Quantitative Trait Locus 3

Genetic Tests for Bone Mineral Density Quantitative Trait Locus 3

Anatomical Context for Bone Mineral Density Quantitative Trait Locus 3

MalaCards organs/tissues related to Bone Mineral Density Quantitative Trait Locus 3:

40
Bone, Liver, Heart, Kidney, Breast, Brain, Bone Marrow

Publications for Bone Mineral Density Quantitative Trait Locus 3

Articles related to Bone Mineral Density Quantitative Trait Locus 3:

(show top 50) (show all 2778)
# Title Authors PMID Year
1
Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. 61 6
23644456 2013
2
The cannabinoid receptor type 2 (CNR2) gene is associated with hand bone strength phenotypes in an ethnically homogeneous family sample. 57 61
19565271 2009
3
Association of the -381T/C promoter variation of the brain natriuretic peptide gene with low bone-mineral density and rapid postmenopausal bone loss. 61 57
12601551 2003
4
Comparison of genome screens for two independent cohorts provides replication of suggestive linkage of bone mineral density to 3p21 and 1p36. 57 61
12478480 2003
5
Variance component linkage analysis indicates a QTL for femoral neck bone mineral density on chromosome 1p36. 57 61
11689491 2001
6
First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q. 61 57
9781060 1998
7
A genome-wide linkage scan for low spinal bone mineral density in a single extended family confirms linkage to 1p36.3. 57
18285824 2008
8
Multiple genetic loci for bone mineral density and fractures. 57
18445777 2008
9
Cannabinoid receptor type 2 gene is associated with human osteoporosis. 57
16204352 2005
10
The (CA)n polymorphism of the TNFR2 gene is associated with peak bone density in Chinese nuclear families. 57
15886863 2005
11
Linkage disequilibrium between polymorphisms in the human TNFRSF1B gene and their association with bone mass in perimenopausal women. 57
12217957 2002
12
Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide. 57
9482886 1998
13
Osteomalacia caused by atypical renal tubular acidosis with vitamin D deficiency: a case report. 61
33398781 2021
14
Prevalence of osteoporosis and osteopenia assessed by densitometry in Japanese puerperal women. 61
33559219 2021
15
Vitamin D supplementation associated with 12-weeks multimodal training in older women with low bone mineral density: A randomized double-blind placebo-controlled trial. 61
33421538 2021
16
Is denosumab associated with an increased risk for infection in patients with low bone mineral density? A systematic review and meta-analysis of randomized controlled trials. 61
33793076 2021
17
Anorexia Nervosa and Osteoporosis. 61
33666707 2021
18
Disease Damage Accrual and Low Bone Mineral Density in Female Patients with Systemic Lupus Erythematosus. 61
33787331 2021
19
Osteoclastogenesis and sphingosine-1-phosphate secretion from human osteoclast precursor monocytes are modulated by the cystic fibrosis transmembrane conductance regulator. 61
33188942 2021
20
New mandibular indices in cone beam computed tomography to identify low bone mineral density in postmenopausal women. 61
32843313 2021
21
Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density. 61
33638863 2021
22
Assessing the Relationship Between Bone Density and Loss of Reduction in Nonsurgical Distal Radius Fracture Treatment. 61
33741214 2021
23
Testosterone Therapy Effects on Bone Mass and Turnover in Hypogonadal Men with Type 2 Diabetes. 61
33735389 2021
24
Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age. 61
32584996 2021
25
Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy. 61
33437642 2021
26
Bone quality assessed by trabecular bone score in severe anorexia nervosa: A brief report. 61
33778960 2021
27
Sleep disturbance and bone mineral density, risk of falls and fracture: Results from a 10.7-year prospective cohort study. 61
33766805 2021
28
Bone Mineral Density Testing in Patients Undergoing Total Ankle Arthroplasty: Should We Pay More Attention to the Bone Quality? 61
33187901 2021
29
Association Between Liver Fat and Bone Density is Confounded by General and Visceral Adiposity in a Community-Based Cohort. 61
33528915 2021
30
Effect of Tibolone on Bone Mineral Density in Postmenopausal Women: Systematic Review and Meta-Analysis. 61
33802101 2021
31
Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic. 61
33301960 2021
32
Investigation of the Effect of Bone Mineral Density on the Postoperative Outcome of Ankle Fractures in Elderly Patients. 61
33719642 2021
33
Comparable incidence of periprosthetic tibial fractures in cementless and cemented unicompartmental knee arthroplasty: a systematic review and meta-analysis. 61
33528591 2021
34
Opportunistic use of dual-energy X-ray absorptiometry to evaluate lumbar scoliosis. 61
33624177 2021
35
Silencing Proteasome 26S Subunit ATPase 2 (PSMC2) Protects the Osteogenic Differentiation In Vitro and Osteogenesis In Vivo. 61
33625534 2021
36
Bone mineral density assessment by DXA in rheumatic patients with end-stage osteoarthritis undergoing total joint arthroplasty. 61
33573628 2021
37
Clinical characteristics and outcomes of patients presenting with hip fractures at a tertiary care hospital in Pakistan. 61
33559020 2021
38
Mandibular cortical index in the screening of postmenopausal at low mineral density risk: a systematic review. 61
33591840 2021
39
Interventions to Improve Bone Mineral Density, Muscle Mass and Fat Mass among Breast Cancer Survivors. 61
33570477 2021
40
Schaaf-Yang Syndrome 61
33570896 2021
41
A New Cause of Obesity Syndrome Associated with a Mutation in the Carboxypeptidase Gene Detected in Three Siblings with Obesity, Intellectual Disability and Hypogonadotropic Hypogonadism 61
32936766 2021
42
Nrf2 epigenetic derepression induced by running exercise protects against osteoporosis. 61
33637693 2021
43
High prevalence and undertreatment of osteoporosis in elderly patients undergoing total hip arthroplasty. 61
33575911 2021
44
Mechanisms of Bone Impairment in Sickle Bone Disease. 61
33668588 2021
45
The Effects of Walking or Nordic Walking in Adults 50 Years and Older at Elevated Risk of Fractures: A Systematic Review and Meta-Analysis. 61
33571958 2021
46
Associations of seasonal patterns and vitamin D levels with onset and flares of pediatric inflammatory bowel disease. 61
28472874 2021
47
Associations between bone attenuation and prevalent vertebral fractures on chest CT scans differ with vertebral fracture locations. 61
33594489 2021
48
Bone Status According to Neurofibromatosis Type 1 Phenotype: A Descriptive Study of 60 Women in France. 61
33558959 2021
49
Assessing underlying bone quality in spine surgery patients: a narrative review of dual-energy X-ray absorptiometry (DXA) and alternatives. 61
32890786 2021
50
A novel approach for evaluating bone mineral density of hips based on Sobel gradient-based map of radiographs utilizing convolutional neural network. 61
33677167 2021

Variations for Bone Mineral Density Quantitative Trait Locus 3

ClinVar genetic disease variations for Bone Mineral Density Quantitative Trait Locus 3:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LGR4 NM_018490.4(LGR4):c.376C>T (p.Arg126Ter) SNV association 55922 rs587777005 GRCh37: 11:27412666-27412666
GRCh38: 11:27391119-27391119
2 BMP4 NM_001202.6(BMP4):c.614T>C (p.Val205Ala) SNV Uncertain significance 562181 rs1566579495 GRCh37: 14:54417363-54417363
GRCh38: 14:53950645-53950645
3 PRDM2 NM_001135610.2(PRDM2):c.511+30415_511+30417dup Duplication Benign 979162 GRCh37: 1:14106394-14106395
GRCh38: 1:13779899-13779900

Expression for Bone Mineral Density Quantitative Trait Locus 3

Search GEO for disease gene expression data for Bone Mineral Density Quantitative Trait Locus 3.

Pathways for Bone Mineral Density Quantitative Trait Locus 3

GO Terms for Bone Mineral Density Quantitative Trait Locus 3

Sources for Bone Mineral Density Quantitative Trait Locus 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....